Spinal Muscular Atrophy Clinical Trials 2023

What are the top hospitals conducting spinal muscular atrophy research?

When it comes to advancing the treatment options for spinal muscular atrophy (SMA), several hospitals are leading the way in clinical trials. In Aurora, Colorado, Children's Hospital Colorado is actively involved in nine ongoing SMA trials and has conducted a total of 17 trials dedicated to this rare genetic condition. Since their first recorded trial in 2012, they have been committed to finding innovative solutions for patients with SMA. Similarly, Ann & Robert H. Lurie Children's Hospital of Chicago has eight ongoing trials and a history of nine completed studies since initiating their first SMA trial in 2012.

Boston Children's Hospital, located in the heart of Boston's medical hub, is also making strides with seven active SMA trials and an impressive track record of conducting 17 previous studies since their inception into researching this condition back in 2012. Meanwhile, on the East Coast at Children's Hospital of The King's Daughters in Norfolk, Virginia researchers are currently engaged with six active SMA clinical trials while having contributed to eight earlier investigations following its pioneering efforts only three years ago starting from 2018.

Heading westward brings us to Stanford University Medical Center situated in Palo Alto where five active spinal muscular atrophy trials are underway alongside six earlier-held experiments that began as recently as four years ago duringthe yearperiodof2016.Organizations such as these play a crucial role by bringing together talented medical professionals who work tirelessly towards improving the lives of individuals affected by spinal muscular atrophy through cutting-edge research.

These hospitals exemplify dedication and progress when it comes to understanding and treating spinal muscular atrophy. Through rigorous clinical testing within diverse populations across different locations nationwide; discoveries made here can pave new avenues for breakthrough treatments ensuring brighter future not just for those impacted by SMA but potentially other related neurological conditions too

Which are the best cities for spinal muscular atrophy clinical trials?

When it comes to spinal muscular atrophy clinical trials, several cities have emerged as top destinations for research and development. New York leads the pack with 18 active trials focused on studying treatments like Risdiplam, Nusinersen, and Treatment Period. Boston closely follows with 15 ongoing studies examining interventions such as Nusinersen and Risdiplam. Chicago and Palo Alto each offer promising options with 12 and 11 active trials respectively, exploring treatments like Apitegromab, Nusinersen, Risdiplam, and more. Additionally, Aurora in Colorado also showcases its commitment to SMA research through its participation in 11 active trials investigating approaches including Nusinersen treatment. These cities provide individuals affected by spinal muscular atrophy access to cutting-edge clinical trials that hold hope for improved outcomes and quality of life.

Which are the top treatments for spinal muscular atrophy being explored in clinical trials?

Spinal muscular atrophy (SMA) clinical trials are exploring several promising treatments to combat this debilitating condition. Leading the pack is risdiplam, currently under investigation in seven active trials for SMA. Since its introduction in 2016, it has accumulated a total of 11 clinical trials dedicated to treating this disease. Another frontrunner is nusinersen, which is being studied in five ongoing SMA trials and has been listed since 2012 with a total of 11 clinical trials so far. Lastly, apitegromab shows potential with one active trial and two all-time SMA studies since its recent listing in 2022. These developments hold promise for patients affected by SMA and offer hope for improved treatment options moving forward.

What are the most recent clinical trials for spinal muscular atrophy?

Exciting developments are unfolding in the realm of spinal muscular atrophy (SMA), as recent clinical trials offer potential breakthroughs for patients. Notably, cohort 1 of a Phase 2 trial has become available, shedding light on new treatment avenues. Additionally, a Phase 3 trial focusing on the treatment period showcases promising advancements in SMA management. OAV-101 and risdiplam, both in Phase 3 trials, provide further hope for improved outcomes and quality of life for individuals with SMA. Furthermore, taldefgrobep alfa's Phase 3 trial results have generated significant interest within the medical community. These recent studies hold promise to transform SMA care and bring renewed optimism to those affected by this condition.

What spinal muscular atrophy clinical trials were recently completed?

Recently, two clinical trials have concluded, offering new insights and potential treatments for spinal muscular atrophy (SMA). In September 2021, Novartis Pharmaceuticals completed a trial evaluating the efficacy of OAV101. This milestone highlights ongoing efforts to combat SMA. Additionally, in February 2021, Hoffmann-La Roche wrapped up its risdiplam trial. These advancements hold promise for patients affected by this debilitating condition and exemplify the dedication of researchers in their quest to improve SMA treatment options.